Clinical trial execution is the most time-consuming and capital-intensive phase of pharmaceutical drug development. The median time from first patient enrolled to regulatory submission is approximately eight years for a novel drug. Adaptive trial designs, decentralized and hybrid clinical trials, and AI-assisted patient recruitment are simultaneously compressing trial timelines, improving success probability, and reducing cost per trial. FDA’s Project Facilitate, Complex Innovative Trial Design program, and guidance documents on decentralized clinical trials have created a framework for sponsors to adopt innovative designs with regulatory confidence.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Adaptive Trial Design
• Decentralized Clinical Trials
• AI in Trial Execution
• Real-World Evidence Integration
• Patient Recruitment and Retention
• Regulatory Framework
Table of Contents
1. Executive Summary
2. Landscape Overview
3. Adaptive Trial Design
4. Decentralized Clinical Trials
5. AI in Trial Execution
6. Real-World Evidence Integration
7. Patient Recruitment and Retention
8. Regulatory Framework
9. Competitive Landscape
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Program and Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Johnson & Johnson
Roche
Novartis
Merck
AstraZeneca
Bristol-Myers Squibb
AbbVie
Eli Lilly
Sanofi
